Intratumoral microbiota remodeling of the tumor microenvironment impact solid tumor immunotherapy.

ABSTRACT: Tumor immunotherapy has significantly advanced in recent years. However, few patients with solid tumors respond to immunotherapy. The tumor microenvironment (TME) is a key factor in immunotherapy efficacy, and the intratumoral microbiota plays a significant role in remodeling the TME. Recent multiomic analyses revealed bacterial signatures in up to 76% of pancreatic ductal adenocarcinoma (PDAC) cases, and specific microbial consortia were linked to therapeutic resistance. Microbiota-targeted therapies, such as engineered bacterial strains, increase tumor clearance rates by approximately 30% in preclinical models. However, the complexity of microbial mechanisms and heterogeneity among individuals limit the clinical translation of intratumoral microbiota-based therapies. In this review, we p

SUBMITTER: Jia J 

PROVIDER: S-EPMC12828053 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature